Gene expression profiling of B-CLL in Ukrainian patients in post-chernobyl period

Experimental Oncology

Volumn 34, Issue 1, 2012, Pages 57-63

  Savli, H ^a   Sunnetci, D ^a   Cine, N ^a   Gluzman, D F ^b   Zavelevich, M P ^b   Sklyarenko, L M ^b   Nadgornaya, V A ^b   Koval, S V ^b  

^a KOCAELI UNIVERSITY   (Turkey)

^b R E KAVETSKY INSTITUTE OF EXPERIMENTAL PATHOLOGY   (Ukraine)

Author keywords

B CLL; Gene expression profiling; Gene networks; Microarray analysis

Indexed keywords

ARACHIDONIC ACID; BETA 2 MICROGLOBULIN; CALCIUM; CD38 ANTIGEN; CYTOCHROME P450; FAS ANTIGEN; G PROTEIN COUPLED RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 1ALPHA; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INITIATION FACTOR 2; LINOLEIC ACID; MYC PROTEIN; PREGNANCY SPECIFIC BETA1 GLYCOPROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN CDC42; PROTEIN RB1; PROTEIN SATB1; PROTEIN YWHAG; UNCLASSIFIED DRUG; XENOBIOTIC AGENT;

ANTIGEN DETECTION; ARTICLE; B CELL LEUKEMIA; BLOOD SAMPLING; BONE MARROW EXAMINATION; CALCIUM SIGNALING; CANCER CLASSIFICATION; CANCER PATIENT; CHERNOBYL ACCIDENT; CHRONIC LYMPHATIC LEUKEMIA; COMPARATIVE STUDY; COMPUTER PROGRAM; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; FATTY ACID METABOLISM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; HUMAN; IMMUNOCYTOCHEMISTRY; INGENUITY PATHWAY ANALYSIS; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MORPHOLOGY; OXIDATIVE PHOSPHORYLATION; RNA ISOLATION; SIGNAL TRANSDUCTION; UBIQUITINATION; UKRAINE; UPREGULATION; WORLD HEALTH ORGANIZATION;

CHERNOBYL NUCLEAR ACCIDENT; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; UKRAINE;

EID: 84862499519     PISSN: 18129269     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Gluzman DF, Nadgornaya VA, Machilo V, et al. Malignant diseases of hematopoietic and lymphoid tissues in Chernobyl clean-up workers. Hematol J 2005; 5: 565-7.
2. th Edn. Philadelphia: WB Saunders, 1996: 195-209.
3. Richardson DB, Wing S, Schroeder J, et al. Ionizing radiation and chronic lymphocytic leukemia. Environ Health Perspect 2005; 113: 1-5.
4. Gluzman D, Imamura N, Sklyarenko L, et al. Patterns of hematological malignancies in Chernobyl clean-up workers (1996-2005). Exp Oncol 2006; 28: 60-3.
5. Zenz T, Mertens D, Küppers R, et al. From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 2010; 10: 37-50.
6. Marinello E, Carlucci F, Rosi F, et al. Purine metabolism in B-cell lymphocytic leukemia: a microarray approach. Nucleosides Nucleotides Nucleic Acids 2006; 25: 1277-81. (Pubitemid 44651889)
7. Savli H, Gluzman DF, Sunnetci D, et al. Quantitative real time PCR analysis of apoptosis-related gene expression in leukemias in Ukrainian patients. Exp Oncol 2011; 33: 104-6.
8. WHO classification of tumours of haematopoietic and lymphoid tissues. Ed. by Swerdlow SH, Campo E, Harris NL et al. Lyon, IARC 2008. 439 p.
9. Savli H, Aalto Y, Nagy B, Knuutila S, Pakkala S. Gene expression analysis of 1,25(OH)2D3-dependent differentiation of HL-60 cells: a cDNA array study. Br J Haematol 2002; 118: 1065-70. (Pubitemid 35025970)
10. Savli H, Karadenizli A, Kolayli F, et al. Expression stability of six housekeeping genes: A proposal for resistance gene quantification studies of Pseudomonas aeruginosa by real-time quantitative RT-PCR. J Med Microbiol 2003; 52: 403-8. (Pubitemid 36589166)
11. Gaiger A, Heintel D, Jdger U. Novel molecular diagnostic and therapeutic targets in chronic lymphocytic leukaemia. Eur J Clin Invest 2004; 34: 25-30.
12. Codony C, Crespo M, Abrisqueta P, et al. Gene expression profiling in chronic lymphocytic leukaemia. Best Pract Res Clin Haematol 2009; 22: 211-22.
13. Delgado MD, León J. Myc roles in hematopoiesis and leukemia. Genes Cancer 2010; 1: 605-16.
14. Halina A, Artur P, Barbara MK, et al. Alterations in TP53, cyclin D2, c-Myc, p21WAF1/CIP1 and p27KIP1 expression associated with progression in B-CLL. Folia Histochem Cytochem 2010; 48: 534-41.
15. Vallat L, Magdelynat H, Merle-Byral H, et al. The resistance of B-CLL cells to DNA damage-induced apoptosis defined by DNA microarrays. Blood 2003; 101: 4598-606. (Pubitemid 36857833)
16. Kyo S, Takakura M, Taira T, et al. Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT). Nucleic Acids Res 2000; 28: 669-77. (Pubitemid 30068249)
17. Bharti AC, Aggarwal BB. Nuclear factor-kappa B and cancer: its role in prevention and therapy. Biochem Pharmacol 2002; 64: 883-8. (Pubitemid 35238030)
18. Liu Z, Hazan-Halevy I, Harris DM, et al. STAT-3 activates NF-kappaB in chronic lymphocytic leukemia cells. Mol Cancer Res 2011; 9: 507-15.
19. Savli H, Szendrtsi A, Romics I, Nagy B. Gene network and canonical pathway analysis in prostate cancer: a microarray study. Exp Mol Med 2008; 40: 176-85. (Pubitemid 351738723)
20. Fraser CC. G protein-coupled receptor connectivity to NF-kappaB in inflammation and cancer. Int Rev Immunol 2008; 27: 320-50.
21. Ho MK, Su Y, Yeung WW, Wong YH. Regulation of transcription factors by heterotrimeric G proteins. Curr Mol Pharmacol 2009; 2: 19-31.
22. Giannoni P, Scaglione S, Quarto R, et al. An interaction between hepatocyte growth factor and its receptor (c-MET) prolongs the survival of chronic lymphocytic leukemic cells through STAT3 phosphorylation: a potential role of mesenchymal cells in the disease. Haematologica 2011; 96: 1015-23.
23. Cho EC, Mitton B, Sakamoto K. CREB and leukemogenesis. Crit Rev Oncol 2011; 16: 37-46.
24. Gachet S, Ghysdael J. Calcineurin/NFAT signaling in lymphoid malignancies. Gen Physiol Biophys 2009; 28: F47-54.
25. Medyouf H, Ghysdael J. The calcineurin/NFAT signaling pathway: a novel therapeutic target in leukemia and solid tumors. Cell Cycle 2008; 7: 297-303. (Pubitemid 351366491)
26. McFadyen MC, Melvin WT, Murray GI. Cytochrome P450 enzymes: novel options for cancer therapeutics. Mol Cancer Ther 2004; 3: 363-71. (Pubitemid 39193712)
27. Antosz H, Kitlin'ska J, Kwiatkowska-Drabik B, et al. Rb1 gene expression in B-cell lymphocytic leukaemia cases with deletion in the 13q14 region. Cytobios 1997; 92: 111-21. (Pubitemid 127531870)
28. Crossen PE. Genes and chromosomes in chronic B-cell leukemia. Cancer Genet Cytogenet 1997; 94: 44-51. (Pubitemid 27133500)
29. Lu X, Cheng C, Zhu S, et al. SATB1 is an independent prognostic marker for gastric cancer in a Chinese population. Oncol Rep 2010; 24: 981-7.
30. Selinger CI, Cooper WA, Al-Sohaily S, et al. Loss of special AT-rich binding protein 1 expression is a marker of poor survival in lung cancer. J Thorac Oncol 2011; 6: 1179-89.
31. Chapiro E, Russell L, Radford-Weiss I, et al. Overexpression of CEBPA resulting from the translocation t(14;19)(q32;q13) of human precursor B acute lymphoblastic leukemia. Blood 2006; 108: 3560-3.
32. Mercher T, Gilliland DG. CEBPA dosage in leukemogenesis. Blood 2006; 108: 3234.
33. Santana-Lemos BA, de Lima Lange AP, de Lira Benício MT, et al. The CEBPA gene is down-regulated in acute promyelocytic leukemia and its upstream promoter, but not the core promoter, is highly methylated. Haematologica 2011; 96: 617-20.
34. Chandra D, Singh KK. Genetic insights into OXPHOS defect and its role in cancer. Biochim Biophys Acta 2011; 1807: 620-5.
35. Sequeira SJ, Wen HC, Avivar-Valderas A, et al. Inhibition of eIF2alpha dephosphorylation inhibits ErbB2-induced deregulation of mammary acinar morphogenesis. BMC Cell Biol 2009; 10: 64.
36. Lee T, Pelletier J. Eukaryotic initiation factor 4F: a vulnerability of tumor cells. Future Med Chem 2012; 4: 19-31.
37. Chung J, Grammer TC, Lemon KP, et al. PDGF-and insulin-dependent pp70S6k activation mediated by phosphatidylinositol-3-OH kinase. Nature 1994; 370: 71-5.
38. Kwon HK, Bae GU, Yoon JW, et al. Constitutive activation of p70S6k in cancer cells. Arch Pharm Res 2002; 25: 685-90.
39. Harhaj EW, Dixit VM. Deubiquitinases in the regulation of NF-χB signaling. Cell Res 2011; 21: 22-39.
40. Vega FM, Ridley AJ. Rho GTPases in cancer cell biology. FEBS Lett 2008; 582: 2093-101.
41. Ambrogio C, Voena C, Manazza AD, et al. The anaplastic lymphoma kinase controls cell shape and growth of anaplastic large cell lymphoma through Cdc42 activation. Cancer Res 2008; 68: 8899-907.
42. Horie M, Suzuki M, Takahashi E, Tanigami A. Cloning, expression, and chromosomal mapping of the human 14-3-3gamma gene (YWHAG) to 7q11.23. Genomics 1999; 60: 241-3. (Pubitemid 29463684)
43. Autieri MV, Carbone CJ. 14-3-3Gamma interacts with and is phosphorylated by multiple protein kinase C isoforms in PDGF-stimulated human vascular smooth muscle cells. DNA Cell Biol 1999; 18: 555-64. (Pubitemid 29357768)
44. Chen XQ, Yu AC. The association of 14-3-3gamma and actin plays a role in cell division and apoptosis in astrocytes. Biochem Biophys Res Commun 2002; 296: 657-63.
45. Del Poeta G, Bruno A, Del Principe MI, et al. Deregulation of the mitochondrial apoptotic machinery and development of molecular targeted drugs in acute myeloid leukemia. Curr Cancer Drug Targets 2008; 8: 207-22. (Pubitemid 351666857)
46. Greaney P, Nahimana A, Lagopoulos L, et al. A Fas agonist induces high levels of apoptosis in haematological malignancies. Leuk Res 2006; 30: 415-26. (Pubitemid 43254963)
47. Jones DT, Ganeshaguru K, Virchis AE, et al. Caspase 8 activation independent of Fas (CD95/APO-1) signaling may mediate killing of B-chronic lymphocytic leukemia cells by cytotoxic drugs or gamma radiation. Blood 2001; 98: 2800-7.